Flag of the European Union EU Clinical Trials Register Help

Clinical trials for IV infusion of placebo

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    664 result(s) found for: IV infusion of placebo. Displaying page 1 of 34.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2012-003262-41 Sponsor Protocol Number: GO28509 Start Date*: 2013-05-16
    Sponsor Name:Genentech, Inc.
    Full Title: A PHASE II, RANDOMIZED STUDY OF PACLITAXEL WITH GDC-0941 VERSUS PACLITAXEL WITH PLACEBO IN PATIENTS WITH LOCALLY RECURRENT OR METASTATIC BREAST CANCER
    Medical condition: Metastatic Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Completed) AT (Completed) CZ (Completed) GB (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2020-002536-67 Sponsor Protocol Number: ISIS678354-CS3 Start Date*: 2021-04-15
    Sponsor Name:Ionis Pharmaceuticals, Inc.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of AKCEA‑APOCIII‑LRX Administered Subcutaneously to Patients with Familial Chylomicronemia Syndrome (FCS)
    Medical condition: Familial Chylomicronemia Syndrome (FCS)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10059183 Familial hypertriglyceridaemia PT
    20.1 100000004861 10020607 Hyperchylomicronemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) SE (Completed) NO (Completed) FR (Completed) PT (Completed) SK (Completed) HU (Completed) NL (Ongoing) ES (Ongoing) IT (Completed)
    Trial results: View results
    EudraCT Number: 2005-003432-22 Sponsor Protocol Number: EGF104383 Start Date*: 2008-07-03
    Sponsor Name:Glaxo SmithKline Research and Development Limited
    Full Title: A Randomized, Double Blind, Placebo-Controlled, Multicenter, Phase III Study Comparing the Activity of Paclitaxel Plus Trastuzumab Plus Lapatinib to Paclitaxel Plus Trastuzumab Plus Placebo in Wome...
    Medical condition: ErbB2+ Metastatic Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2004-000971-33 Sponsor Protocol Number: A4061010 Start Date*: 2004-09-24
    Sponsor Name:PFIZER
    Full Title: Randomized, Placebo-Controlled, Double-Blind, Phase 2 Study of AG-013736 in Combination With Docetaxel Versus Docetaxel Alone in Patients With Metastatic Breast Cancer Preceded by a Phase 1 Evaluat...
    Medical condition: METASTATIC BREAST CANCER
    Disease: Version SOC Term Classification Code Term Level
    6.1 10055113 PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2010-020101-32 Sponsor Protocol Number: OAM4861g Start Date*: 2010-10-21
    Sponsor Name:GENENTECH, Inc.
    Full Title: A RANDOMIZED, PHASE II, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE SAFETY AND EFFICACY OF METMAB IN COMBINATION WITH PACLITAXEL AND BEVACIZUMAB IN PATIENTS WITH METASTATIC, ...
    Medical condition: Metastatic, triple-negative breast cancer Cáncer de mama metastásico triple negativo
    Disease: Version SOC Term Classification Code Term Level
    12.1 10055113 Breast cancer metastatic PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Completed) FR (Completed) BE (Completed) DE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2014-000469-35 Sponsor Protocol Number: GO29227 Start Date*: 2014-08-12
    Sponsor Name:Genentech, Inc.
    Full Title: A RANDOMIZED, PHASE II, MULTICENTER, PLACEBO-CONTROLLED STUDY OF IPATASERTIB (GDC-0068), AN INHIBITOR OF AKT, IN COMBINATION WITH PACLITAXEL AS FRONT-LINE TREATMENT FOR PATIENTS WITH METASTATIC TRI...
    Medical condition: Inoperable locally advanced or metastatic triple negative breast cancer
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10027475 Metastatic breast cancer LLT
    17.0 100000004864 10072740 Locally advanced breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed) BE (Completed) ES (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2011-005335-97 Sponsor Protocol Number: GO25632 Start Date*: 2012-10-11
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A phase III, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of bevacizumab, and associated biomarkers, in combination with paclitaxel compared w...
    Medical condition: HER2-negative metastatic breast cancer.
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004864 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) BE (Prematurely Ended) GB (Prematurely Ended) IT (Prematurely Ended) BG (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-003862-40 Sponsor Protocol Number: BO17708 Start Date*: 2006-01-20
    Sponsor Name:F. Hoffmann-La Roche Limited
    Full Title: Estudio multicéntrico, randomizado, doble ciego, controlado con placebo, para evaluar la eficacia y seguridad de bevacizumab en combinación con docetaxel, en comparación con docetaxel más placebo, ...
    Medical condition: Cáncer de mama metastásico Metastatic breast cancer
    Disease: Version SOC Term Classification Code Term Level
    8 10055113 PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Completed) BE (Completed) AT (Completed) GB (Completed) SE (Completed) PT (Completed) DE (Completed) LT (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-001588-37 Sponsor Protocol Number: CRLX030A2202 Start Date*: 2011-11-29
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A multicenter, randomized, double-blind, parallel group, placebo-controlled study to evaluate the renal hemodynamic effects of RLX030 at a dose of 30 μg/kg/day or placebo infused for 24 hours in su...
    Medical condition: Chronic heart failure with worsening of symptoms like shortness of breath at rest or minimal exertion
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004849 10008908 Chronic heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) NL (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2008-008697-31 Sponsor Protocol Number: CRAD001W2301 Start Date*: 2009-11-12
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized Phase III, double-blind, placebo-controlled multicenter trial of daily everolimus in combination with trastuzumab and vinorelbine, in pretreated women with HER2/neu over-expressing loc...
    Medical condition: HER2-neu overexpressing metastatic breast cancer after previous trastuzumab use
    Disease: Version SOC Term Classification Code Term Level
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055113 Breast cancer metastatic PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed) GR (Completed) BE (Completed) IT (Completed) ES (Completed) FR (Completed) CZ (Completed) GB (Completed) HU (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2011-002913-12 Sponsor Protocol Number: M12-895 Start Date*: 2012-05-15
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Randomized, Phase 2 Study of the Efficacy and Tolerability of Veliparib in Combination with Temozolomide or Veliparib in Combination with Carboplatin and Paclitaxel Versus Placebo Plus Carboplati...
    Medical condition: BRCA1 or BRCA2 mutation metastatic breast cancer
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) HU (Completed) DK (Completed) SK (Completed) FI (Completed) SE (Completed) BE (Completed) NL (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2012-003507-35 Sponsor Protocol Number: AV-951-12-204 Start Date*: 2013-05-20
    Sponsor Name:AVEO Pharmaceuticals, Inc.
    Full Title: A Phase 2 Randomized, Double-Blind, Placebo-Controlled, 2-Arm, Multi-Center Study Comparing Tivozanib Hydrochloride In Combination With Paclitaxel Versus Placebo In Combination With Paclitaxel in t...
    Medical condition: Locally recurrent and/or metastatic triple negative breast cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10006193 Breast cancer NOS recurrent LLT
    14.1 100000004864 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Prematurely Ended) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-001416-23 Sponsor Protocol Number: FM-B07-01 Start Date*: 2007-08-31
    Sponsor Name:FONDAZIONE MICHELANGELO - AVANZAMENTO DELLO STUDIO E CURA DEI TUMORI
    Full Title: A Multinational Double-Blind, Randomized Phase IIb Cooperative Group Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo when Administered in Combination with Chemotherapy and...
    Medical condition: Patients with Locally Recurrent or Metastatic Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10055113 Breast cancer metastatic LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Prematurely Ended) DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-002240-40 Sponsor Protocol Number: I4T-MC-JVCU Start Date*: 2015-04-10
    Sponsor Name:Eli Lilly and Company
    Full Title: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Capecitabine and Cisplatin With or Without Ramucirumab as First-line Therapy in Patients With Metastatic Gastric or Gastroesophageal ...
    Medical condition: Metastatic gastric adenocarcinoma or gastroesophageal junction (GEJ) denocarcinoma
    Disease: Version SOC Term Classification Code Term Level
    17.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10063916 Metastatic gastric cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) DE (Completed) FI (Completed) NL (Completed) IT (Completed) ES (Completed) PL (Completed) BE (Completed) GB (Completed) CZ (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2011-005932-24 Sponsor Protocol Number: CBKM120F2202 Start Date*: 2012-07-24
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, double-blind, placebo controlled, phase II/III study of BKM120 plus paclitaxel in patients with HER2 negative inoperable locally advanced or metastatic breast cancer, with or without ...
    Medical condition: This study will evaluate whether the addition of daily BKM120 to weekly paclitaxel is effective and safe in treating patients with HER2- locally advanced or metastatic breast cancer.
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004864 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: AT (Completed) CZ (Completed) ES (Temporarily Halted) NL (Completed) GB (Completed) BE (Completed) HU (Completed) IT (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2007-003384-51 Sponsor Protocol Number: 20060341 Start Date*: 2007-12-11
    Sponsor Name:Amgen Inc.
    Full Title: A Randomized, 4-Arm, Placebo-Controlled Phase 2 Trial of AMG 386 in Combination with Bevacizumab and Paclitaxel or AMG386 plus Paclitaxel as First-Line Therapy in Subjects with Her2-Negative, Metas...
    Medical condition: Her2-Negative, Metastatic or Locally Recurrent Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Completed) GB (Completed) AT (Completed) BE (Completed) DK (Completed) FI (Completed) NL (Completed) ES (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2013-002377-21 Sponsor Protocol Number: M14-011 Start Date*: 2014-11-17
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Randomized, Placebo-Controlled, Double-Blind, Phase 3 Study Evaluating Safety and Efficacy of the Addition of Veliparib Plus Carboplatin Versus the Addition of Carboplatin to Standard Neoadjuvant...
    Medical condition: Triple Negative Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Completed) DE (Completed) CZ (Completed) HU (Completed) GB (GB - no longer in EU/EEA) ES (Completed) IT (Completed) PL (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2021-002192-19 Sponsor Protocol Number: ISIS678354-CS5 Start Date*: 2022-07-22
    Sponsor Name:Ionis Pharmaceuticals, Inc.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of ISIS 678354 Administered Subcutaneously to Patients with Severe Hypertriglyceridemia
    Medical condition: Severe hypertryglyceridemia
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10059183 Familial hypertriglyceridaemia PT
    20.1 100000004861 10020607 Hyperchylomicronemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Trial now transitioned) NO (Trial now transitioned) ES (Ongoing) FR (Trial now transitioned) HU (Trial now transitioned) NL (Trial now transitioned) CZ (Trial now transitioned) FI (Trial now transitioned) BG (Trial now transitioned) SK (Trial now transitioned) PT (Trial now transitioned) PL (Trial now transitioned) DK (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-005067-32 Sponsor Protocol Number: I4T-MC-JVCZ Start Date*: 2015-11-24
    Sponsor Name:Eli Lilly and Company
    Full Title: Protocol I4T-MC-JVCZ Randomized Phase 2 Trial Evaluating Alternative Ramucirumab Doses in Combination with Paclitaxel in Second-Line Metastatic or Locally Advanced, Unresectable Gastric or Gast...
    Medical condition: Second-Line Metastatic or Locally Advanced, Unresectable Gastric or Gastroesophageal Junction Adenocarcinoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10063916 Metastatic gastric cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed) SE (Completed) GR (Completed) BE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2015-000897-36 Sponsor Protocol Number: AB14005 Start Date*: 2016-04-26
    Sponsor Name:AB science
    Full Title: A prospective, multicentre, double-blind, randomized, placebo-controlled, phase 3 study to evaluate efficacy and safety of masitinib with irinotecan in patients with advanced-stage esophagogastric ...
    Medical condition: Πatients with advanced-stage esophagogastric adenocarcinoma who have relapsed after first-line chemotherapy
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004864 10017776 Gastric carcinoma stage III LLT
    18.1 100000004864 10017777 Gastric carcinoma stage IV NOS LLT
    18.1 100000004864 10017778 Gastric carcinoma stage IV without metastases LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed May 07 08:41:12 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA